Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Charles River Laboratories › CEO received an award of 17K CRL shares Insider trades
Why it stands out Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Mar 2, 2026
Reporting period Not applicable
Filed with the SEC Mar 4, 2026 CEO Grant / award
Context Classification grant award
Code A — grant or award
Planned / mechanical clue Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001100682-26-000026
Filed / recorded
Mar 4, 2026, 9:42 PM UTC
Added to OQRO Oct 2, 2026, 12:27 PM UTC
Data quality Verified: identifiers matched exactly
Issuer CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Reporting person James C Foster
Relationship Director, Officer
Officer title Chairman, President and CEO
Table Non-derivative (Table I)
Transaction date Mar 2, 2026
Acquired / disposed Acquired (A)
Shares owned after 279,693
Footnotes from the filing 100% of the unvested restricted stock units vest on March 2, 2028. Reflects the exempt transfer pursuant to Rule 16a-13 of 9,220 shares from the 2025 GRAT account to direct holdings.
Around the same time Fund moves
18 tracked managers disclosed the same change for Q1 2026. From a 13F filed Apr 1, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Mar 4 · filed 1 day later
Gift or transfer — classified separately from trades.
Federal contracts
Health and Human Services awardedUpdated 9mo ago Development and maintenance of a multigenotypic aged rat colony
The Department of Health and Human Services has committed $1.92M to Charles River Laboratories so far. It runs until Jan 19, 2027.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 22, 2025 Insider Officer sold ~$65K of CRL shares in the open market Jan 8, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On January 8, 2026, the Board of Directors (the “Board”) of Charles River Laboratories International, Inc. (the “Company”) announced a leadership transition plan.” Jan 13, 2026 Company filing · Form 8-K · Results, Reg FD Reported its results, and shared information with investors Jan 20, 2026 Federal contract · $1.9M obligated Department of Health and Human Services awarded Charles River Laboratories: $1.92M obligated to date Feb 10, 2026 5% stake Wellington Management Group LLP reported a passive stake (13G) of 3.6% Feb 12, 2026 5% stake Invesco Ltd. reported a passive stake (13G) of 5.5% Feb 18, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer. Mr. Coleman will join the company with a tentative start date of April 6, 2026.” Feb 18, 2026 Company filing · Form 8-K · Results Reported its results Feb 25, 2026 Federal contract · $936K obligated Department of Health and Human Services awarded Charles River Laboratories: $936K obligated to date What came next Mar 3, 2026 Insider · First insider buy since Feb 2025 Officer purchased ~$4.4K of CRL shares in the open market Mar 26, 2026 5% stake The Vanguard Group reported a passive stake (13G) Apr 29, 2026 5% stake Vanguard Capital Management reported a passive stake (13G) of 7.4% May 5, 2026 Company filing · Form 8-K · Executive change, Shareholder vote Changed a top executive or board member, and held a shareholder vote “On May 5, 2026, Charles River Laboratories International, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”). As further discussed below, at the Annual Meeting, the shareholders of the Company approved the Company’s 2026 Long-Term Incentive Plan (the “2026 Incentive Plan”).”